Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
3.095
+0.235 (8.22%)
At close: Jun 26, 2026, 4:00 PM EDT
3.050
-0.045 (-1.45%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Cadrenal Therapeutics Employees
Cadrenal Therapeutics had 5 employees as of December 31, 2025. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change (1Y)
1
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$2,377,704
Market Cap
8.88M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 1 | 25.00% |
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 1 | 33.33% |
| Dec 31, 2022 | 3 | - | - |
| Sep 30, 2022 | 1 | - | - |
| Jun 30, 2022 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| Bolt Biotherapeutics | 23 |
| AIM ImmunoTech | 21 |
| CalciMedica | 16 |
| MetaVia | 8 |
| Immuron | 7 |
| Quoin Pharmaceuticals | 6 |
| Kairos Pharma | 4 |
CVKD News
- 2 days ago - Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress - GlobeNewsWire
- 8 days ago - Cadrenal Therapeutics to file for FDA RPDD for tecarfarin in Kawasaki Disease - TheFly
- 8 days ago - Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease - GlobeNewsWire
- 11 days ago - Cadrenal Therapeutics to initiate CAD-1005 trial - TheFly
- 11 days ago - Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026 - GlobeNewsWire
- 23 days ago - Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event - GlobeNewsWire
- 4 weeks ago - Cadrenal Therapeutics Transcript: Lytham Partners Spring 2026 Investor Conference - Transcripts
- 5 weeks ago - Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 - GlobeNewsWire